Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Change in Prostate Cancer Bone Metastases Following Radium-223
NCT03062254Phase 2Completed
- Sponsor
- Jewish General Hospital
- Start
- Mar 2018
- Primary completion
- Jul 2020
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Jewish General Hospital. Started Mar 2018; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03062254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062254.